Traditional vaccines have seen spectacular successes in eradicating smallpox and have come close to eradicating poliomyelitis also. However, 
and the recent deadly but narrow-ranged Nipah virus with 40% fatalities among infected persons in Malaysia and 75% to 100% fatalities in Bangladesh and India [8, 9] , to name a few. The suddenness and pathologic intensity in each instance caught the world unaware, with no therapeutics to combat the diseases or provide relief to the patients except for palliatives and culling of domestic poultry and animals as suspected carriers of the virus. These were all either new viruses or, as in the case of the H1N1, a mutated form of an older version [10] . In any case, no existing drugs or vaccines were capable of meeting these onslaughts and generating new drugs and vaccines is time consuming and expensive.
On average, it takes about 10-15 years [11] and costs approximately US$1.8 to US$2.6 billion [12, 13] to discover and develop a new drug. Tens of thousands of compounds need to be introduced into the drug discovery pipeline for every successful drug that comes to the market [14] . The cost of developing a vaccine-from research and discovery to product registration-is estimated to be between US$200 million and US$500 million per vaccine. This figure includes vaccines that are abandoned during the development process. In short, vaccine research and product development is also a lengthy and complex process loaded with binary outcome risks [15] . Since viral epidemics generally die out within six to eighteen months, similar exercises would be clearly an inadequate approach to such epidemics and pandemics. In some instances, like the hypervariable ribonucleotide (RNA) viruses like influenza, the viruses mutate so rapidly that their vaccines have to be in a constant change regime.
Traditional vaccines such as attenuated or inactivated vaccines have to go through a lengthy process to breed, purify, store-sometimes, as in the case of the rVSV-ZEBOV Ebola vaccine, at −60 to −80 °C [16] , and transport to the point of administration; there is also the other problem of necessarily the same vaccine having to target different communities, not all of which will exhibit the same level of response efficiency. To meet all this diversity, regular changes in the vaccines are required, which becomes a complex task and not commercially viable. Then also, sudden calls for increased supply often surpasses the ability to manufacture good quality vaccines as has happened in the Ebola virus outbreak in the Democratic Republic of Congo in 2019 where the supplies of the rVSV-ZEBOV Ebola vaccine is reported to be less than required and necessary production will require 6-18 months [17] .
Clearly, an effective alternative is urgently required. [18] [19] [20] [21] , the science of vaccine design that focuses attention on how vaccines operate and then build on that information, rather than blindly replicate old techniques. The main idea is to understand that the body's defense mechanism will operate upon the suitable surface exposed proteins, the epitopes, of the virion and act to eliminate the virus [22] ; indeed, the first successful peptide vaccine was one used against the canine parvovirus [23] , and since then several peptide vaccines for veterinary use have been licensed and marketed [24, 25] , though none for human use so far. Severing out the relevant surface exposed parts from the full virion and using appropriate peptides as vaccine candidates may help elicit the same defensive apparatus into action as for traditional vaccines (see Figure 1 for a simple schematic of peptide vaccines), but at less time and cost and thus spread the benefits of vaccination to cover more viruses and more people than current vaccines permit. This is in principle a doable scenario once the genetic structure of the virus is known, and that is not difficult these days with superfast sequencer machines and advances in computational technology. The technique is to scan the pathogens' proteins for binding with Human Leukocyte Antigen (HLA) which vary from person to person and community to community. Peptide vaccines have been proposed against viral diseases [26] and human cancers [27] , with notable successes against cancer tumors [28] . The pick of the peptides that could act as vaccines is determined by the binding of the processed peptide with the major histocompatibility complex (MHC) class I and II molecules coupled with the relevant HLA to be presented on the surface of the antigen presenting cells (APC) for determining the antibodies. Use of non-live vaccines so derived for humoral and cellular immunity avoids introducing any infectious organisms that may cause unintended illnesses in recipient individuals. Indeed, peptide vaccines have become very efficacious in cancer tumor treatment and has come to constitute a fourth pillar for such treatment complementing surgery, chemotherapy and radiation [28] .
Compared with whole cell lysates or proteins, the peptide based approach has an advantage that only epitopes of interest are loaded onto the immune system instead of whole lot of irrelevant antigens that may lead to autoimmune response. The other advantage of peptide vaccines is that they can be fine-tuned by modifications to enhance the binding with MHCs to heighten the immunogenicity, a process called epitope enhancement [28] . Together, these attributes can be exploited for specific 
PERSONALIZED VACCINES
Personalized vaccines have made a huge impact in cancer treatment.
Yoshida et al. [29] reports from a study of 500 advanced cancer patients The prognosis for pancreatic cancer, however, remains rather bleak.
In an earlier report, Yamamoto et al. [30] had reported that matching the HLA profiles of 11 pancreatic cancer individuals and administering only reactive peptide vaccines (max 4) that increased cellular and humoral immune responses to at least one of the peptides used for vaccination were observed in 10 patients and the survival rates for 6-and 12-months were seen to be 80% and 20% respectively. Injection sites were seen to be inflamed in 7 patients, but overall the regimen was well tolerated. The authors concluded that these encouraging results warranted further study of personalized peptide-based immunotherapy for pancreatic cancer.
Obara et al. [31] reports that in urological cancer cases the immune response of small peptides has been rather limited due to various factors Perhaps the most individualistic drug ever made is the case of manufacture of milasen, a splice-modulating antisense oligonucleotide drug tailored to one particular patient to treat a fatal but rare neurodegenerative condition [32] . The exercise was facilitated by molecular diagnosis that led to the rational design, testing and manufacture of the novel drug and offers a possible template for future development of patient-customized therapeutics. However, a number of ethical, commercial and social issues remain that needs to be carefully considered before such individualized approaches can become accessible for the many [33] .
VIRAL EPIDEMICS STRATEGY
The case for peptide vaccines against viral epidemics is not as strong [34, 35] . Generally, the community first facing the epidemic is the front-runner in the analyses and research for producing the vaccine which leads to T-cell and B-cell proliferation in case of strong binding. At the next stage we embark on two parallel exercises. Taking adequate number of the surface protein sequences, we use a web server like SABLE or iTASSER to determine the hydrophilicity levels of the sequence. At the same time we take all the sequences and determine which parts of the sequence remain most conserved through all the mutations that our library of these sequences suggest. To determine this,
we use a simple 20-dimensional graphical representation and numerical characterization of protein sequences to map a window of 10 to 12 amino acids to a descriptor number (see Ref [41] for method, Ref [38] for application). We start from the beginning of a sequence to calculate the segment descriptor, then move the window by one amino acid position and calculate the second descriptor, and so on till the end of the sequence.
We next do this for the remaining sequences until we have a matrix of amino acid position numbers versus segment descriptors for all the sequences. Running through the descriptors at each amino acid position, we can determine how many different descriptors there were, which implies that the lesser the variety of descriptors, the more conserved will that segment be. Such an exercise can be done by using other models of protein characterization (see Ref [42] ), but we find our 20D method easier to use and sufficient for our purposes. Now, with the hydrophilicity profile and the protein variety profile on hand, we search for those domains where the surface exposure of the protein segment is highest and variability the least signifying the best regions for designing peptide vaccines, which may turn out to be more than one for a surface protein;
we found six regions in influenza neuraminidase, four in the Zika envelope protein. One additional step we take is to check with the protein 3D structure diagram, if available, to ensure that the regions we pick for high surface exposure is not covered by neighboring protein structures.
The next step is to determine the epitope potential of the selected regions. For this we use the IEDB analyses resource with its library of HLA profiles of the community we wish to cover and also check for linear and conformational epitopes. If strong binding is seen between the antigen and the HLA in the regions we had selected in the process described above, then that would be indicative of strong vaccine possibility, else we have to delete that region from our list. Similarly, we need to check for autoimmune threats, if any, from these peptides and reduce the final list of peptides that meet all our criteria and form a part cancers where the success rate is found to be comparatively very high.
PROS AND CONS OF PEPTIDE VACCINES
However, there are issues with peptide vaccines at this nascent stage.
As remarked by Li et al. [43] , the safety of particulate peptide vaccine delivery systems remains a major concern. Administration of the the full virion is exposed to the host immune system. Use of adjuvants helps rectify this deficiency to a large extent, but the science behind adjuvants is just beginning to be understood [45, 46] . Then there are worries about stability of a peptide in vivo, for which carrier proteins need to be used.
But the positives outweigh the negatives by far [21] . More than one peptide can be combined as multivalent vaccines, the peptides being chemical entities can be manufactured to high levels of purity as well as scaled up to produce huge quantities in a short period of time, their storage at normal room temperature removes many worries of storing in have been used for computer-assisted drug discovery protocols [48, 49] .
Because experimental data on such peptides designed in silico will be difficult to obtain, the clustering can be done using computed molecular descriptors which can be calculated from the structure (primary sequence) of the peptides without requirement of any other laboratory-generated data. Peptide vaccines, in short, are the answer to several of the problems that plague the development, production, dissemination and administration of traditional vaccines. These are of expeditious concern since many of the viral epidemics that plague a nation occur in the tropical and warmer temperate climates where funding issues often deter the use of the best of modern drugs and vaccines.
The fact remains, however, that to date no peptide vaccines have been licensed for human use. Given the positive feedbacks received from trials of peptide vaccines against cancer tumors [28] and infectious diseases [50] , as well as the many advantages of peptide vaccines [21, 51] , it would appear possible that impediments to successful implementation of such vaccines will be overcome and licensure for peptide vaccines will ensue sometime in the near future.
If and when that does happen, there can be special benefits of peptide vaccine technology in the face of viral epidemics and pandemics. One can envisage a scenario where a string of peptide vaccine factories will be spread strategically located around the globe, while one or two labs are designated for detailed analysis of the epidemic/pandemic virus. On successful identification of the peptides through in silico and in vitro/in vivo analyses, the peptide sequences can be distributed to the peptide vaccine factories that can then commence to minor adjustments for epitope enhancement [52] to ensure best fit to the prevailing community HLA profiles. The same procedure can be adopted to cater to the requirements of immunocompromised individuals to ensure vaccination in these cases also. In the case of cancer victims, personalized vaccine development is a necessary condition for further treatment. 
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